Verlingue Acquires the Insurance Broker Cabinet Depeyre, a Specialist in Complex Corporate Risks, and the Underwriting Agency Depeyre Solutions
11.1.2023 16:15:00 EET | Business Wire | Press release
Verlingue, a subsidiary of the French Adelaïde Group, specialising in corporate protection, is continuing its external growth strategy with two new acquisitions that will consolidate its presence in the Grand Est region (France).
Set up in 1997, the insurance broker Cabinet Depeyre specialises in consulting and management of complex business risks. Depeyre Solutions, created in 2014, is an underwriting agency specialising in business risks for brokers and general agents. The group has 23 employees for just over €4m in commissions.
The insurance broker Cabinet Depeyre, specialised in complex business risks, works with its customers to analyse, prevent and manage their risks. The Cabinet Depeyre teams have acquired special expertise in high-pressure sectors such as the wood processing industry, transport and logistics, manufacturers and traders of building materials, etc., whether in matters of Civil Liability or Property Damage.
Depeyre Solutions, which is intended to remain an autonomous entity affiliated to the Adelaïde Group, sells insurance solutions as an underwriting agent (MGA) for business risks, mainly in the fields of Vehicle Fleet, Property Damage and Civil Liability.
“With Verlingue, I firmly believe that our teams will be able to provide even better support to our customers and provide them with all the solutions offered by a company with which we already share common values and a vision of our role as a trusted partner in risk management,” says Jean-Michel Depeyre, head of both companies.
After the acquisition of RT Global Insurance in Portugal at the end of 2022, the acquisition of Cabinet Depeyre and Depeyre Solutions in France consolidates Verlingue's external growth dynamic as part of its 2024 strategic plan.
“Verlingue has a powerful, sustainable and profitable growth strategy in place. In a consolidating business sector, being a family-owned broker with an ambitious and long-term vision allows us to map out great plans for the teams that decide to join our adventure. I’m delighted that Jean-Michel Depeyre has jumped on board,” says Gilles Bénéplanc – CEO of the Adelaide Group and Verlingue.
About Verlingue
An insurance broker specializing in business protection, Verlingue is a subsidiary of the Adelaïde Group.
Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its clients’ value creation and performance.
With offices in France, Portugal, Great Britain and Switzerland, and through partners in over 100 countries, Verlingue works with its clients over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).
1,200 employees, 400 of whom are based outside France
€2.2bn in premiums negotiated on behalf of its clients
24 offices in Europe
LinkedIn / www.verlingue.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005440/en/
Contact information
Press contact:
Adelaïde Group - Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom